VISTA
Get twice-weekly insights on the biggest stories shaping cardiology.
You might also like
Cardiology Pharmaceuticals May 8, 2025
Marea Makes Progress on MAR001 May 8, 2025
Marea Therapeutics presented positive data from the Phase 2a clinical trial of its fat-targeting monoclonal antibody, MAR001, that could help address lipid and metabolic drivers of ASCVD. To assess MAR001’s impact on remnant cholesterol and triglycerides, researchers randomized 55 patients with hypertriglyceridemia to one of three doses (150, 300, and 450mg) or placebo and found… […]
Cardiology Pharmaceuticals May 8, 2025
Obicetrapib Puts on a Show May 8, 2025
Results from NewAmsterdam Pharma’s Phase 3 BROADWAY and TANDEM trials suggest that obicetrapib could be an effective LDL-C lowering treatment, both on its own or combined with another drug. TANDEM examined the effects of a fixed-dose obicetrapib/ezetimibe combination therapy and found… BROADWAY put on a one-man show for obicetrapib as a monotherapy to help confirm […]
Surgeries & Interventions May 5, 2025
FDA Approves TAVR for Asymptomatic AS May 5, 2025
TAVR will officially be an option for asymptomatic patients with severe aortic stenosis following the FDA’s approval of Edwards Lifesciences’ SAPIEN 3 platform for the patient group. EARLY TAVR was the first RCT designed to evaluate TAVR compared to watchful waiting for patients with asymptomatic severe AS. These results helped inform the FDA’s decision, but […]
